Curie Therapeutics Appoints Kapil Dhingra, MBBS, to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curie Therapeutics Inc. ("Curie"), a biotechnology company focused on developing precision radiopharmaceutical therapies for solid tumors, today announced the appointment of Kapil Dhingra, MBBS, to its Board of Directors.
“I am excited to welcome Kapil to our Board of Directors,” said Simon Read, Curie’s CEO and Founder. “Kapil is widely recognized as a thought leader in oncology research and development. His leadership has been key to the approval of a number of milestone oncology drugs, including Herceptin®, Tarceva®, Avastin®, Zelboraf® and Perjeta®. As a member of the board of Advanced Accelerator Applications and Algeta, he also has rich experience in radiopharmaceutical discovery and development including next generation products such as those targeting PSMA and marketed products such as Lutathera® (lutetium Lu 177 dotatate). His expertise will support Curie’s ambition to transform the treatment of a wide range of solid tumors.”
“It’s an honor to join Curie’s Board of Directors,” said Dr. Dhingra. “I am impressed by the thoughtful approach taken by Curie to create the next generation of radiopharmaceuticals that will have the potential to transform the treatment of a wide variety of cancers. The strong leadership team at Curie has developed a novel platform that takes an integrated approach to creating novel radiopharmaceutical drug candidates optimized against a variety of targets with high unmet medical need. The strength and depth across the company in radiobiology, radiochemistry and cancer biology coupled with the investment in a fully integrated company that brings together key functions under the same roof positions the company well to make rapid progress in realizing this promise.”
Dr. Dhingra is a medical oncologist and a physician-scientist. He trained at the All India Institute of Medical Sciences in New Delhi, India, and completed internal medicine residency at Lincoln Medical and Mental Health Center, New York and hematology and oncology fellowship at Emory University School of Medicine. Dr. Dhingra then served on faculty at The University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Dhingra’s transition to industry initiated at Eli Lilly in Clinical Research, and continued at Roche, where, as Vice President of Oncology he led its growth into a global leader. Throughout his industry career, Dr. Dhingra maintained an academic faculty appointment, initially at Indiana University School of Medicine and subsequently, at Memorial Sloan Kettering Cancer Center. Since 2008, he has been an independent consultant to numerous oncology companies. Dr. Dhingra serves on the Boards of Directors of Lava Therapeutics (as Chairman of the Board), Black Diamond Therapeutics, Inc., Replimune, Inc., Median Technologies, and Autolus Therapeutics plc. He previously served on the boards of Five Prime Therapeutics, Inc., Biovex, Micromet, Algeta, YM Biosciences, Epitherapeutics, Advanced Accelerator Applications, and Exosome Diagnostics, which were all acquired by major pharmaceutical companies.
About Curie Therapeutics
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie’s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie’s mission is to revolutionize the use of radiomedicines in cancer. Learn more at www.curietherapeutics.com
Media: Sarah Sutton
IR: Kevin Murphy